Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey.

Background/aim: The aim of this descriptive article is to share the experience in Ege University, Turkey with favipiravir in the treatment of severe SARS-CoV-2 pneumonia.

Materials And Methods: This retrospective descriptive study included patients diagnosed with COVID-19 who presented with or developed severe pneumonia.

Results: Forty patients who completed a full course (at least 5 days) of favipiravir were included in the study.